Neisseria meningitidis causes meningitis, fulminant septicemia or mild meningococcemia attacking mainly children and young adults. Lipopolysaccharides (LPS) consist of a symmetrical hexa-acyl lipid A and a short oligosaccharide chain and are classified in 11 immunotypes. Lipid A is the primary toxic component of N. meningitidis . LPS levels in plasma and cerebrospinal fluid as determined by Limulus amebocyte lysate (LAL) assay are quantitatively closely associated with inflammatory mediators, clinical symptoms, and outcome. Patients with persistent septic shock, multiple organ failure, and severe coagulopathy reveal extraordinarily high levels of LPS in plasma. The cytokine production is compartmentalized to either the circulation or to the subarachnoid space. Mortality related to shock increases from 0% to > 80% with a 10-fold increase of plasma LPS from 10 to 100 endotoxin units/ml. Hemorrhagic skin lesions and thrombosis are caused by up-regulation of tissue factor which induces coagulation, and by inhibition of fibrinolysis by plasminogen activator inhibitor 1 (PAI-1). Effective antibiotic treatment results in a rapid decline of plasma LPS (half-life 1—3 h) and cytokines, and reduced generation of thrombin, and PAI-1. Early antibiotic treatment is mandatory. Three intervention trials to block lipid A have not significantly reduced the mortality of meningococcal septicemia.
References
1.
Vieusseux M.Mémoire sur la maladie qui a régné a Genève au printemps de 1805. J Méd Chir Pharm1805 ; 11: 163—182.
2.
Weichelbaum A.Ueber die Aetiologie der akuten Meningitis cerebrospinalis. Fortschr Med1887; 5: 573—583.
3.
Andrewes FWA case of acute meningococcal septicaemia. Lancet1906; I: 1172—1173.
4.
Waterhouse R.A case of suprarenal apoplexy. Lancet1911; I: 577—578.
5.
Friderichsen C.Nebennierenapoplexie bei kleinen Kindern. Jb Kinderheilk1919; 87: 109—125.
6.
Kolle W., Wassermann A.Versuche zur Gewinnung und Wertbestimmung eines Meningococcenserums . Deutsch Med Wschr1906; 32: 609—612.
7.
Jochmann G.Versuche zur Serodiagnostik und Serotherapie der epidemischen Genickstarre . Deutsch Med Wschr1906; 32: 788—793.
8.
Netter A, Debré R. (eds) La Méningite Cérebro-spinale. Paris: Masson, 1911; 47—82, 245—282.
Flexner S.The results of the serum treatment in thirteen hundred cases of epidemic meningitis . J Exp Med1913; 17: 553—576.
11.
Caugant DAPopulation genetics and molecular epidemiology of Neisseria meningitidis . APMIS1998; 106: 505—525.
12.
van Deuren M., Brandtzaeg P., van der Meer Jwm.Update on meningococcal disease with emphasis on pathogenesis and clinical management . Clin Microb Rev2000; 13: 144—166.
13.
Cartwright K.Meningococcal carriage and disease. In: Cartwright K. (ed) Meningococcal Disease. Chichester, John Wiley , 1995; 115—146.
14.
Stephens DSUncloaking the meningococcus: dynamics of carriage and disease. Lancet1999; 353: 941—942.
15.
Stephens DS , Farley MMPathogenetic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae . Rev Infect Dis1991; 13: 22—33.
16.
De Vries FP , van der Ende A., van Putten JP, Dankert J.Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect Immun1996; 64: 2998—3006.
17.
Brandtzaeg P.Pathogenesis of meningococcal infections. In: Cartwright K. (ed) Meningococcal Disease. Chichester: John Wiley , 1995; 71—114.
18.
Brandtzaeg P., Kierulf P., Gaustad P. et al. Plasma endotoxin as predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis1989; 159: 195—204.
19.
Brandtzaeg P., Halstensen A., Kierulf P., Espevik T., Waage A.Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock . Microb Pathogen1992; 13: 423—431.
20.
Brandtzaeg P, vstebø R, Kierulf P. Bacteremia and compartmentalization of LPS in meningococcal disease. In: Levin J , Alving CR, Munford R, Redl H. (eds) Lipopolysaccharides from Genes to Therapy. New York: Wiley-Liss, 1995; 219—233.
21.
Brandtzaeg P.Systemic meningococcal disease: clinical pictures and pathophysiological background. Rev Med Microbiol1996; 7: 63—72.
22.
Kirsch EA, Barton RP, Kitchen L., Giroir BPPathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J1996; 15: 967—978.
23.
De Kleijn ED , Hazelzet JA, Kornelisse RF, de Groot R.Pathophysiology of meningococcal sepsis in children. Eur J Pediatr1998; 157: 869—880.
24.
Tzeng YL, Stephens DSEpidemiology and pathogenesis of Neisseria meningitidis. Microb Infect2000; 2: 687—700.
Uronen H., Williams AJ, Dixon G. et al. Gram-negative bacteria induce pro-inflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS). Clin Exp Immunol2000; 122: 312—314.
27.
Ingalls RR, Lien E., Golenbock DTMembrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through Toll-like receptor 2. Infect Immun2001; 69: 2230—2236.
28.
Pridmore AC , Wyllie DH, Abdillahi F. et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2 . J Infect Dis2001; 183: 89—96.
29.
Dixon Glj, Newton PJ, Chain BM et al. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. Infect Immun2001; 69: 4351—4357.
30.
Sprong T., Stikkelbroeck N., van der Ley P. et al. Contributions of Neisseria meningitidis LPS and non-LPS to pro-inflammatory cytokine response. J Leukoc Biol2001; 70: 283—288.
31.
DeVoe IW, Gilchrist JERelease of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med1973; 138: 1156—1167.
32.
Stephens DS , Edwards KM, Morris F., McGee ZAPili and outer membrane appendages on Neisseria meningitidis in cerebrospinal fluid of an infant. J Infect Dis1982; 146: 568.
33.
Brandtzaeg P., Bryn K., Kierulf P. et al. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest1992 ; 89: 816—823.
34.
Fredriksen JH, Rosenquist E., Wedege E. et al. Production, characterization and control of MenB-vaccine `Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann1991; 14: 67—79.
35.
Bjerre A., Brusletto B., Rosenquist E. et al. Cellular activating properties and morphology of membrane-bound and purified meningococcal lipopolysaccharide. J Endotoxin Res2000; 6: 437—445.
36.
Lorenzen DR , Düx F., Wölk U., Tsirpouchtsidis A., Haas G., Meyer TFImmunoglobulin A1 protease, an exoenzyme of pathogenic Neisseriae, is a potent inducer of pro-inflammatory cytokines. J Exp Med1999; 190: 1049—1058.
37.
Bjerre A., Brusletto B., vstebø R., Kierulf P., Brandtzaeg P.Is lipid A the principal monocyte activating factor in meningococcal septic shock plasma?J Endotoxin Res2000; 6: 123.
38.
Steeghs L., den Hartog R., den Boer A., Zomer B., Roholl P., van der Ley P.Meningitidis bacterium is viable without endotoxin. Nature1998; 392: 449—450.
39.
Tsai CM, Frasch C., Rivera E. et al. Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand1989; 17: 229—258.
40.
Reza M., Høiby EA, Holst J., Lyberg T.Outer membrane vesicles from Neisseria meningitidis: effects on cytokine production in human whole blood. Cytokine2001; 13: 91—97.
41.
Lapinet JA, Scapini P., Calzetti F., Pérez O., Cassatella MAGene expression and production of tumor necrosis factor alpha, interleukin-1β (IL-1β), IL-8, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles. Infect Immun2000; 68: 6917—6923.
42.
Alpert G., Baldwin G., Thompson C. et al. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis1992; 165: 494—500.
43.
Baldwin G., Alpert G., Caputo GL et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis1991; 164: 542—549.
44.
Cavaillon JM , Haeffner-Cavaillon N.Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin. Mol Immunol1986; 9: 965—969.
45.
Petrov AB, Semenov BF, Vartanyan YP et al. Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes. Infect Immun1992; 60: 3897-3903.
46.
Roth RI, Yamasaki R., Mandrell RE, Griffiss JMAbility of gonococcal and meningococcal lipopolysaccharides to clot Limulus amebocyte lysate. Infect Immun1992 ; 60: 762—767.
47.
Hazelzet JA , Petrov AB, Stubenitsky R. et al. Cardiovascular aspects of experimental sepsis in young and older awake piglets: age-related differences. Shock1999; 12: 145—154.
48.
Kulshin VA, Zähringer U., Lindner B. et al. Structural characterization of the lipid A component of pathogenic Neisseria meningitidis. J Bacteriol1992; 174: 1793—1800.
49.
L'vov VL, Verner IK, Musina LY, Rodionov AV, Ignatenko AV, Shashkov ASStructure of the sugar-phosphate moiety of lipid A from lipooligosaccharide of Neisseria meningitidis group B, strain BC5S No. 125. Arch Microbiol1992; 157: 131—134.
50.
Kahler CM, Stephens DSGenetic basis for biosynthesis, structure, and function of meningococcal lipopolysaccharide (endotoxin). Clin Rev Microbiol1998; 24: 281—334.
51.
Mandrell RE , Zollinger WDLipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition. Infect Immun1977; 16: 471—475.
52.
Frasch CE, Zollinger WD, Poolman JTSerotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis1985; 7: 504—510.
53.
Griffiss JM, Schneider H.The chemistry and biology of lipooligosaccharides: the endotoxins of bacteria of the respiratory and genital mucosae. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 179—194.
54.
Kosma P.Chemical synthesis of core structures. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 257-281.
55.
Mandrell RE , Kim CM, John CM et al. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol1991 ; 173: 2823—2832.
Jarvik GA, Vedros NASialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun1987; 55: 174—180.
58.
Vogel U., Claus H., Hinze G., Frosch M.Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect Immun1999; 67: 954—957.
59.
van Putten JPM.Phase variation of LPS directs interconversion of invasive and immuno-resistant phenotypes of Neisseria gonorrhoeae. EMBO J1993; 12: 4043—4051.
60.
Jack DL, Dodds AW, Anwar N. et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol1998; 160: 1346—1353.
Hibberd ML, Sumiya M., Summerfield JA, Booy R., Levin M.Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet1999; 353: 1049—1053.
63.
Rietschel ET , Kirikae T., Schade FU et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J1994; 8: 217—225.
64.
Zähringer U. , Lindner B., Rietschel ETChemical structure of lipid A: recent advances in structural analysis of biologically active molecules. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker , 1999; 93—114.
Hall CL, Munford RSEnzymatic deacylation of the lipid A moiety of Salmonella typhimurium lipopolysaccharides by human neutrophils. Proc Natl Acad Sci USA1893; 80: 6671—6675.
67.
Kitchens RL, Munford RSInternalization of lipopolysaccharide by phagocytes. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 521—536.
68.
Van der Ley P., Steeghs L., Hamstra HJ, ten Hove J., Zomer B., van Alphen L.Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity and adjuvant activity. Infect Immun2001; 69: 5981—5990.
69.
Steeghs L.Lipid A engineering in vaccine development against Neisseria meningitidis . Thesis, Utrecht University, The Netherlands 2001; 119—159.
70.
Mandrell RE , Apicella MALipooligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. Immunobiology1993; 187: 382—402.
71.
Giardina PC, Apicella MA, Gibson B., Preston A.Antigenic mimicry in Neisseria species. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 55—65.
72.
Jennings HJ , Johnson KJ, Kenne L.The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res1983; 121: 233—241.
73.
Di Fabio JL , Michon F., Brisson JR, Jennings HJStructure of the L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis. Can J Chem1990; 68: 1029—1034.
74.
Michon F., Beurret M., Gamian A., Brisson JR, Jennings HJStructure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem1990; 265: 7243—7247.
75.
Gamian A., Beurret M., Michon F., Brisson JR, Jennings HJStructure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem1992; 267: 922—925.
76.
Pavliak V., Brisson JR, Michon F., Ulrín D., Jennings HJStructure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis . J Biol Chem1993; 268: 14146—14152.
77.
Apicella MA , Griffiss JM, Schneider H.Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods Enzymol1994; 235: 242—252.
78.
Kim JJ, Phillips NJ, Gibson BW, Griffiss JM, Yamasaki R.Meningococcal group A lipooligosaccharides (LOS ): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes. Infect Immun1994; 62: 1566—1575.
79.
Kogan G., Uhrin D., Brisson JR, Jennings HJStructural basis of the Neisseria meningitidis immunotypes including L4 and L7 immunotypes. Carbohydr Res1997; 298: 191—199.
80.
Tsai CM, Boykins R., Frasch CEHeterogeneity and variation among Neisseria meningitidis lipopolysaccharides . J Bacteriol1983; 155: 498—504.
81.
Schneider H. , Hale TL, Zollinger W., Seid RC, Hammack CA, Griffiss JMHeterogeneity of molecular size and antigenic expression within the lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis . Infect Immun1984; 45: 544—549.
82.
Andersen SR, Bryn K., Thorseng K., Jantzen E.Heterogeneity of lipopolysaccharides of Neisseria meningitidis revealed by thin-layer chromatography combined with monoclonal antibodies. J Microb Methods1996; 25: 187—194.
83.
ScholtenRJPM, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol1994; 41: 236—243.
84.
Jones DM, Borrow R., Fox AJ, Gray S., Cartwright H., Poolman JTThe lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog1992; 13: 219—224.
85.
Moran EE, Brandt BL, Zollinger WDExpression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect Immun1994; 62: 5290—5295.
86.
Hood DW, Moxon ERLipopolysaccharide phase variation in Haemophilus and Neisseria. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 39—54.
87.
Parkhill J. , Achtman M., James KD et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature2000; 404: 502—506.
88.
Tettelin H. , Saunders NJ, Heidelberg J. et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science2000; 287: 1809—1815.
89.
Giardina PC , Gioannini TG, Buscher A. et al. Construction of acetate auxotrophs of Neisseria meningitidis to study host-meningococcal endotoxin interactions . J Biol Chem2001; 276: 5883—5891.
90.
Harthug S., Bjorvatn B., sterud B.Quantitation of endotoxin in blood from patients with meningococcal disease using a Limulus lysate test in combination with chromogenic substrate . Infection1983; 11: 192—195.
91.
Bjorvatn B. , Bjertnaes L., Fadnes HO et al. Meningococcal septicaemia treated with combined plasmaphoresis and leucaphoresis or with blood exchange. BMJ1984; 228: 439—441.
92.
Brandtzaeg P., vstebø R., Kierulf P.Compartmentalization of lipopolysaccharide-production correlates with the clinical presentation in meningococcal disease. J Infect Dis1992 ; 166: 650—652.
93.
Van Deuren M., van der Ven-Jongekrijg J., Bartelink Akm, van Dalen R., Sauerwein RW, van der Meer Jwm.Correlation between pro-inflammatory cytokines and anti-inflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis1995; 172: 433—439.
94.
Brandtzaeg P. , vstebø R., Kierulf P.Quantitative detection of bacterial lipopolysaccharides in clinical specimens. In Pollard AJ, Maiden MCJ. (eds) Meningococcal Disease: Methods and Protocols. Totowa, NJ: Humana , 2001; 427—439.
95.
Suffredini AF , O'Grady NPPathophysiological responses to endotoxin in humans. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Marcel Dekker , 1999; 817—830.
96.
Brandtzaeg P.Halstensen A., Kierulf P., Espevik T., Waage A.Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock . Microb Pathog1992; 13: 423—431.
97.
Prins JM, Speelman P., Kuijper EJ, Dankert J., van Deventer Sjh.No increase in endotoxin during antibiotic killing of meningococci . J Antimicrob Chemother1997; 39: 13—18.
98.
Heyderman RS , Klein NJ, Daramola OA et al. Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microb Pathog1997; 22: 265—274.
99.
Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med1988; 318: 1481—1488.
100.
Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T.The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med1989; 169: 333—338.
101.
Waage A., Halstensen A., Shalaby R., Brandtzaeg P., Kierulf P., Espevik T.Local production of tumor necrosis factor α, interleukin 1, and interleukin 6 in meningococcal meningitis. J Exp Med1989 ; 170: 1859—1867.
102.
Brandtzaeg P. , Waage A., Mollnes TE, ktedalen O., Kierulf P.Severe human septic shock involves more than tumor necrosis factor. In: Sturk A, van Deventer SJH , ten Cate JW, Büller HR, Thijs HR, Levin J. (eds) Bacterial Endotoxins; Cytokine Mediators and New Therapies for Sepsis. New York, Wiley-Liss, 1991; 25—42.
103.
Girardin E. , Grau GE, Dayer JM, Roux-Lombard P., the J5 Study Group, Lambert PHTumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med1988; 319: 387—400.
104.
Hazelzet JA , Risseeuw-Appel I., Kornelisse R.Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost1996; 76: 932—938.
105.
Kornelisse RF, Savelkoul Hfj, Mulder Phg et al. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis . J Infect Dis1996 ; 173: 1498—1502.
106.
Granowitz, EV, Santos AA, Poutsiaka DD et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet1991; 338: 1423—1424.
107.
Van Deuren M., van der Ven-Jongekrijg J., Vannier E. et al. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections . Blood1997; 90: 1101—1108.
108.
Waage A., Espevik T.Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice. J Exp Med1988; 167: 1987—1992.
109.
Van der Poll T., Malefyt Rdw, Coyle SM, Lowry SFAnti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13. J Infect Dis1997; 175: 118—122.
110.
Wong HL, Lotze MT, Wahl LM, Wahl SMAdministration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J Immunol1992; 148: 2118—2125.
111.
Brandtzaeg P., Osnes L., vstebø R., Joø GB, Westvik ÅB, Kierulf P.Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med1996; 184: 51—60.
112.
Fong Y., Moldawer LL, Marano M. et al. Endotoxemia elicits increased circulating β2-INF/IL-6 in man. J Immunol1989; 142: 2321—2324.
113.
Frieling Jtm , van Deuren M., Wijdenes J. et al. Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange . Crit Care Med1996; 24: 1801—1805.
114.
Martish GD, Danner RL, Ceska M., Suffredini AFDetection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med1991; 171: 1021—1024.
115.
Van Zee KJ, DeForge LA, Fischer E. et al. IL-8 in septic shock, endotoxemia, and after IL-1 administration . J Immunol1991; 146: 3478—3482.
116.
Halstensen A. , Ceska M., Brandtzaeg P., Redl H., Naess A., Waage A.Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis1993; 167: 471—475.
117.
Marchant A., Bruyns C., Vandenabeele P. et al. The protective role of interleukin-10 in endotoxin shock. In: Levin J, van Deventer SJH, van der Poll T, Sturk A. (eds) Bacterial Endotoxins: Basic Science to Antisepsis Strategies. New York: Wiley-Liss, 1994; 417—423.
118.
Derkx B., Marchant A., Goldman M., Bijlmer R., van Deventer Sjh.High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis1995 ; 171: 229—232.
119.
Lehmann AK , Halstensen A., Sørnes S., Røkke O., Waage A.High levels of interleukin 10 in serum are associated with fatality in meningococcal disease . Infect Immun1995; 63: 2109—2112.
120.
Kornelisse RF, Hazelzet JA, Savelkoul Hfj et al. The relationship between plasminogen activator inhibitor-1 and pro-inflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis1996; 173: 1148—1156.
121.
Van Deuren M, Netea MG, Hijmans A. et al. Posttranscriptional down-regulation of tumor necrosis factor-alpha and interleukin-beta production in acute meningococcal infections. J Infect Dis1998; 177: 1401—1405.
122.
Lamont AG, Adorini L.IL-12: a key cytokine in immune regulation. Immunol Today1996; 17: 214—217.
123.
Hazelzet JA , Kornelisse RF, van der Pouw Kraan Tctm et al. Interleukin-12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytokine1997; 9: 711—716.
124.
Kornelisse RF, Hack CE, Savelkoul Hfj et al. Intrathecal production of interleukin-12 and interferon-γ in patients with bacterial meningitis. Infect Immun1997; 65: 877—881.
125.
Sauter C., Wolfensberger C.Interferon in human serum after injection of endotoxin. Lancet1980; i: 852—853.
126.
Hesse DG, Tracey KJ, Fong Y. et al. Cytokine appearance in human endotoxemia and primate bacteremia . Surg Gynecol Obstet1988; 166: 147—153.
127.
The J5 Study Group.Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis1992; 165: 695—701.
128.
Bogdan C., Paik J., Vodovotz Y., Nathan C.Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin 10. J Biol Chem1992; 267: 23301—23308.
129.
Van Deventer Sjh, Büller HR, ten Cate JW, Aarden LA, Hack E., Sturk A.Experimental endotoxemia in humans: analysis of the cytokine release and coagulation, fibrinolytic and complement pathways . Blood1990; 76: 2520—2526.
130.
Suffredini AF, Harpel PC, Parrillo JEPromotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin . N Engl J Med1989; 321: 280—287.
131.
Brandtzaeg P. , Kierulf P.Endotoxin and meningococcemia. intravascular inflammation induced by native endotoxin in man. In: Ryan JL, Morrison DC. (eds) Bacterial Endotoxic Lipopolysaccharides, vol. 2 Immunopharmacology and Pathophysiology . Boca Raton, FL: CRC Press, 1992; 327—346.
132.
Hangen DH, Stevens JH, Satoh PS, Hall EW, O'Hanley PT, Raffin TAComplement levels in primates treated with anti-C5a antibodies. J Surg Res1989; 46: 195—199.
133.
Brandtzaeg P., Mollnes TE, Kierulf P.Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis1989; 160: 58—65.
134.
Brandtzaeg P., Høgåsen K., Kierulf P.Mollnes TEThe excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation . J Infect Dis1996; 173: 647—655.
135.
Hazelzet J. , de Groot R., van Mierlo G. et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun1998; 66: 5350—5356.
136.
Høgåsen K. , Mollnes TE, Brandtzaeg P.Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal complement complex and the vitronectin-thrombin-antithrombin complex. Infect Immun1994; 62: 4874—4880.
137.
Oragui EE, Nadel S., Kyd P., Levin M.Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit Care Med2000; 28: 3002—3008.
138.
Taylor FB, Chang Ack, Ruf W. et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock1991; 33: 127—134.
139.
Levi M., ten Cate H., van der Poll T., van Deventer Sjh.Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA1993; 270: 975—979.
140.
ten Cate JW , van der Poll T., Levi M., ten Cate H., van Deventer Sjh.Cytokines: triggers of clinical thrombotic disease. Thromb Haemost1997; 78: 415—419.
141.
Zhang FX, Kirschning CJ, Mancinelli R. et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem1999; 274: 7611—7614.
142.
Faure E., Equils O., Sieling PA et al. Bacterial lipopolysaccharide activates NF-κB through Toll-like receptor (TLR-4) in cultured human dermal endothelial cells. J Biol Chem2000; 275: 11058—11063.
143.
Brandtzaeg P., Dahle JS, Høiby EAThe occurrence and features of hemorrhagic skin lesions in 115 cases of systemic meningococcal disease . NIPH Ann1983; 6: 183—190.
144.
Hill WR, Kinney TDThe cutaneous lesions in acute meningococcemia. JAMA1947; 134: 513—518.
145.
Faust SN, Levin M., Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med2001; 345: 408—416.
146.
van Deuren M., van Dijke BJ, Koopman Rjj et al. Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions . BMJ1993; 306: 1229—1232
147.
Brandtzaeg P., Sandset PM, Joø GB, vstebø R., Kierulf P., Abildgaard U.The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res1989; 55: 459—470.
148.
Leclerc F. , Hazelzet JA, Jude B. et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med1992; 18: 202—205.
149.
Kornelisse RF, Hazelzet JA, Hop Wcj et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis1997 ; 25: 640—646.
150.
Powars DR, Larsen R., Johnson J. et al. Epidemic meningococcaemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis1993 ; 17: 254—261.
151.
Finvandraat K., Derkx B., Peters M. et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost1995; 73: 15—20.
152.
Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344: 699—709.
153.
Brandtzaeg P. , Joø GB, Brusletto B., Kierulf P.Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res1990; 57: 271—278.
154.
Engebretsen LF , Kierulf P., Brandtzaeg P.Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease . Thromb Res1986; 42: 713—716.
155.
Hermans Pwm, Hibberd L., Booy R. et al. 4G/5G promotor polymorphism in the plasminogen activator inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet1999; 354: 556—560.
156.
Pixley RA, De La Cadena R., Page JD et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest1993; 91: 61—68.
157.
Colman RW, Schmaier AHContact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and pro-inflammatory attributes. Blood1997; 90: 3819—3843.
158.
Kirkebøen KA, Strand A.The role of nitric oxide in sepsis — an overview. Acta Anaesthesiol Scand1999; 43: 275—288.
159.
Stiehm ER, Damrosch DSFactors in the prognosis of meningococcal infection. J Pediatr1966; 68: 457—467.
160.
Gedde-Dahl TW, Bjark P., Høiby EA, Høst JH, Bruun JNSeverity of meningococcal disease: assessment by factors and scores and implications for patient management . Rev Infect Dis1990; 12: 973—992.
161.
Derkx Hhf, van den Hoek J., Redekop WK, Bijlmer Rpgm, van Deventer Sjh, Bossuyt Pmm.Meningococcal disease: a comparison of eight severity scores in 125 children . Intensive Care Med1996; 22: 1433—1441.
162.
Brown CC, Malech HL, Gallin JIIntravenous endotoxin recruits a distinct subset of human neutrophils, defined by monoclonal antibody 31D8, from bone marrow to the peripheral circulation . Cell Immunol1989; 123: 294—306.
163.
Suffredini AF, Reda D., Banks MS, Tropea M., Agosti JM, Miller R.Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration . J Immunol1995; 155: 5038—5045.
164.
Dormehl IC , Maree M., Cromarty D. et al. Investigation by scintigraphic methods of neutrophil kinetics under normal and septic shock conditions in the experimental baboon model. Eur J Nucl Med1990: 16: 643—647.
165.
Johne B., Fagerhol MK, Lyberg T. et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. MolPathophysiol1997; 50: 113—123.
166.
Heyderman RS, Ison CA, Peakman M., Levin M., Klein NJNeutrophil response to Neisseria meningitidis: inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability increasing protein (rBPI21) . J Infect Dis1999; 179: 1288—1292.
167.
Waring PM, Presneill J., Maher DW et al. Differential alternations in plasma colony-stimulating factor concentrations in meningococcemia. Clin Exp Immunol1995; 102: 501—506.
168.
Bøyum A., Tennfjord VA, Gran C., Løvhaug D., ktedalen O., Brandtzaeg P.Bioactive cytidine deaminase, an inhibitor of granulocyte-macrophage-colony forming cells, is massively released in fulminant meningococcal sepsis. J Infect Dis2000; 182: 1784—1787.
169.
sterud B., Flaegstad T.Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to unfavourable prognosis. Thromb Haemost1983; 49: 5—7.
170.
Nieuwland R., Berckmans RJ, McGregor S. et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood2000; 95: 930—935.
171.
van Deuern M., Neeleman C., van't Hek Lgfm, van der Meer Jwm.A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course . Intensive Care Med1998 ; 24: 157—161.
172.
Bjerre A., vstebø R., Kierulf P., Halvorsen S., Brandtzaeg P.Fulminant meningococcal septicemia: dissociation between plasma thrombopoietin and platelet counts. Clin Infect Dis2000; 30: 643—647.
173.
Brandtzaeg P., ktedalen O., Kierulf P., Opstad PKElevated VIP and plasma endotoxin in human Gram-negative septic shock. Regul Pept1989 ; 24: 37—44.
174.
Revhaug A. , Lygren I., Jenssen TG, Giercksky KE, Burhol PGVasoactive intestinal peptide in sepsis and shock. Ann N Y Acad Sci1988; 527: 536—545.
175.
Bredius Rgm , Derkx Bhf, Fijen Cap et al. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children . J Infect Dis1994; 170: 848—853.
176.
Fijen CA, Bredius RG, Kuijper EJ et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement deficient individuals . Clin Exp Immunol2000; 120: 338—345.
177.
Westendorp Rgj, Hottenga JJ, Slagboom PEVariation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet1999; 354: 561—563.
178.
Nadel S., Newport MJ, Booy R., Levin M.Variation in the tumor necrosis factor-α gene promotor region may be associated with death from meningococcal disease. J Infect Dis1996; 174: 878—880.
179.
Westendorp Rgj, Langemans Jam, Huizinga Twj et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet1997 ; 349: 170—173.
180.
Westendorp Rgj, Langemans Jam, Huizinga Twj, Verweij CL, Sturk A.Genetic influence on cytokine production in meningococcal disease. Lancet1997; 349: 1912—1913.
181.
Derkx B., Wittes J., McCloskey R.Randomized placebo-controlled trial of HA-1A, a human monoclonal anti-endotoxin antibody, in children with meningococcal septic shock. Clin Infect Dis1999; 28: 770—777.
182.
Levin M., Quint PA, Goldstein B. et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet2000; 356: 961—967.
183.
Baumgartner JD, Heumann D., Calandra T., Glauser MPAntibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis1991; 163: 769—772.
184.
Chan B., Kalabalikis P., Klein N., Heyderman R., Levin M.Assessment of the effect of candidate anti-inflammatory treatment on the interaction between meningococci and inflammatory cells in vitro in a whole blood model . Biotherapy1996; 9: 221—228.
185.
Van Deuren M, Brandtzaeg P.Parents' and GPs' key role in diagnosis of meningococcal septicaemia. Lancet2000; 356: 954—955.
